Literature DB >> 26258842

A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism.

Lin Du1, Ling Shan1, Bing Wang1, Honghua Li1, Zhida Xu2, Wouter G Staal3, Feiyong Jia1,4,5.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the therapeutic effects of combined bumetanide and applied behavior analysis (ABA) treatment in children with autism.
METHODS: Sixty children diagnosed with autism according to the International Classification of Diseases, Tenth Revision (ICD-10) criteria (mean age of 4.5 years) were randomly divided into two groups: A single treatment group (n=28) and a combined treatment group (n=32). The combined treatment group received ABA training combined with oral bumetanide (0.5 mg twice a day). The single treatment group received ABA training only. Autism symptoms were evaluated with the Autism Behavior Checklist (ABC) and the Childhood Autism Rating Scale (CARS), whereas severity of disease (SI) and global improvement (GI) were measured with the Clinical Global Impressions (CGI). Assessment of ABC, CARS, and CGI was performed immediately before and 3 months after initiation of the treatment(s).
RESULTS: Prior to intervention(s) no statistically significant differences in scores on the ABC, CARS, SI, or GI were found between the two groups. Total scores of the ABC, CARS, and SI were decreased in both groups after 3 months (p<0.05) compared with the scores prior to treatment. The total scores of the ABC and the CGI were significantly (p<0.05) lower in the combined treatment group than in the single treatment group. Although the total and item scores of the CARS in the combined treatment group were lower than in the single treatment group after a 3 month intervention, they did not reach statistical significance. No adverse effects of bumetanide were observed.
CONCLUSIONS: Treatment with bumetanide combined with ABA training may result in a better outcome in children with autism than ABA training alone.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26258842     DOI: 10.1089/cap.2015.0045

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  25 in total

Review 1.  Is birth a critical period in the pathogenesis of autism spectrum disorders?

Authors:  Yehezkel Ben-Ari
Journal:  Nat Rev Neurosci       Date:  2015-07-08       Impact factor: 34.870

Review 2.  Revisiting the excitation/inhibition imbalance hypothesis of ASD through a clinical lens.

Authors:  Russell G Port; Lindsay M Oberman; Timothy Pl Roberts
Journal:  Br J Radiol       Date:  2019-06-11       Impact factor: 3.039

3.  The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder.

Authors:  Qingyang Li; Lingli Zhang; Haidi Shan; Juehua Yu; Yuan Dai; Hua He; Wei-Guang Li; Christelle Langley; Barbara J Sahakian; Yin Yao; Qiang Luo; Fei Li
Journal:  Transl Psychiatry       Date:  2022-06-03       Impact factor: 7.989

4.  Right Anterior Theta Hypersynchrony as a Quantitative Measure Associated with Autistic Traits and K-Cl Cotransporter KCC2 Polymorphism.

Authors:  Simge Aykan; Meghan H Puglia; Canan Kalaycıoğlu; Kevin A Pelphrey; Timur Tuncalı; Erhan Nalçacı
Journal:  J Autism Dev Disord       Date:  2021-02-26

5.  Bumetanide for autism: Open-label trial in six children.

Authors:  Elisabeth Fernell; Peik Gustafsson; Christopher Gillberg
Journal:  Acta Paediatr       Date:  2021-01-21       Impact factor: 2.299

6.  Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details.

Authors:  Yehezkel Ben-Ari; Eric Delpire
Journal:  Epilepsia       Date:  2021-02-03       Impact factor: 6.740

7.  Effect of the Early Start Denver Model on Children With Autism Spectrum Disorder Syndrome of Different Traditional Chinese Medicine Types in Northeast China.

Authors:  Lili Wang; Junyan Feng; Yu Zhang; Tiantian Wang
Journal:  Front Pediatr       Date:  2022-03-29       Impact factor: 3.418

Review 8.  Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments.

Authors:  Maria Jimena Salcedo-Arellano; Ana Maria Cabal-Herrera; Ruchi Harendra Punatar; Courtney Jessica Clark; Christopher Allen Romney; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2020-11-19       Impact factor: 7.620

9.  Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).

Authors:  Véronique Crutel; Estelle Lambert; Pierre-François Penelaud; Cristina Albarrán Severo; Joaquin Fuentes; Antoine Rosier; Amaia Hervás; Stéphane Marret; Guiomar Oliveira; Mara Parellada; Simon Kyaga; Sylvie Gouttefangeas; Marianne Bertrand; Denis Ravel; Bruno Falissard
Journal:  J Autism Dev Disord       Date:  2021-08

Review 10.  Novel Concepts for the Role of Chloride Cotransporters in Refractory Seizures.

Authors:  Pavel A Kipnis; Shilpa D Kadam
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.